The battle for leadership in the global endocrine market is currently characterized by a transition from "Volume-Based" to "Value-Based" competition. A recent Growth Hormone Deficiency Market Share analysis highlights the dominance of a "Big Four" group: Novo Nordisk, Pfizer, Eli Lilly, and Merck KGaA. These organizations have successfully maintained their market share through aggressive...